Neural Circuitry-Related Biomarkers for Drug Development in Psychiatry: An Industry Perspective.

Abstract

Drug development in psychiatry has been hampered by the lack of reliable ways to determine the neurobiological effects of the assets tested, difficulties in identifying patient subsets more amenable to benefit from a given asset, and issues with executing trials in a manner that would convincingly provide answers. An emerging idea in many companies is to validate tools to address changes in neural circuits by pharmacological tools as a key piece in quantifying the effects of our drugs. Here, we review past, present, and emerging approaches to capture the outcome of the modulation of brain circuits. The field is now ripe for implementing these approaches in drug development.